Register Login
Register to leave comments
  • News bot March 12, 2026, 12:07 p.m.

    📋 CENTURY THERAPEUTICS, INC. (IPSC) - Financial Results

    Filing Date: 2026-03-12

    Accepted: 2026-03-12 08:05:44

    Event Type: Financial Results

    Event Details:

    CENTURY THERAPEUTICS, INC. (IPSC) Reports the reporting period Financial Results CENTURY THERAPEUTICS, INC. (IPSC) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 109164
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 61853
      • 813, our top priority and a program we believe has the potential to functionally cure type 1 diabetes. Recent achievements, including compelling preclinical results combined with constructive interactions with the FDA, strengthen our confidence in the clinical path ahead. We plan to submit an IND as early as the fourth quarter of this year and anticipate initial clinical data in the second half of
      • We are energized by the progress across our pipeline, confident in the road ahead, and focused on advancing our most promising programs into the clinic.” Fourth Quarter 2025 and Recent Highlights Pipeline ·CNTY
      • 813, priority program for type 1 diabetes, advancing through IND
        • expected in 2026
        • anticipated initial clinical data in 2H 2027
        • expected in 4Q 2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 3.65K 4.76K $-1.10K -23.20%
    Current Assets Property Equipment Net 50.03K 62.14K $-12.12K -19.50%
    Current Assets Operating Lease Right Of Use Assets 16.14K 28.71K $-12.57K -43.78%
    Current Assets Intangible Assets Net 34.20K 34.20K $0.00 +0.00%
    Current Liabilities Accounts Payable 4.77K 3.08K $1.70K +55.22%
    Operating Expenses Interest Income 7.35K 13.01K $-5.66K -43.52%
    Operating Expenses Other Income Net 275.00 354.00 $-79.00 -22.32%
    Operating Expenses Net Loss 9.58K 126.57K $-116.99K -92.43%
    Operating Expenses Net Loss Per Share 0.14 1.61 $-1.47 -91.30%
    Prepaid Expenses and Other Current Assets 3.65K 4.76K $-1.10K -23.20%
    Property and Equipment, Net 50.03K 62.14K $-12.12K -19.50%
    Accounts Payable 4.77K 3.08K $1.70K +55.22%
    Revenue 109.16K 6.59K $102.58K +1556.76%
    Loss from Operations 17.27K 138.14K $-120.87K -87.50%
    Interest Income 7.35K 13.01K $-5.66K -43.52%
    Other Income, Net 275.00 354.00 $-79.00 -22.32%
    Net Loss 9.58K 126.57K $-116.99K -92.43%

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: CENTURY THERAPEUTICS, INC.
    • Ticker Symbol: IPSC

Search

News categories